The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Acta oncologica

• Publication date

  2014-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/0284186X.2014.895036PMID 24666267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

  2014cited by this paper
• Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

  2013influential reference
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cited by this paper
• Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

  2013cited by this paper
• Promising biomarkers for predicting the outcomes of patients with KRAS wild‐type metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A systematic review with meta‐analysis

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

  2012cited by this paper
• Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

  2012cited by this paper
• PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

  2012cited by this paper
• Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

  2012cited by this paper
• Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

  2012cited by this paper
• The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

  2012cited by this paper
• Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

  2011cited by this paper
• Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

  2011cited by this paper
• A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

  2011cited by this paper
• Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

  2011cited by this paper
• Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

  2011cited by this paper
• Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients

  2011cited by this paper
• Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

  2010cited by this paper
• Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010influential reference
• Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

  2009influential reference
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

  2009influential reference
• PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

  2009cited by this paper
• Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

  2009cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

  2009cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

  2007cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Ras proteins: different signals from different locations

  2003cited by this paper
• Summary of recommendations: The Evaluation of Genomic

  year unknowncited by this paper

• Single‑center weakly supervised deep learning prediction of KRAS, NRAS, BRAF, and HER2 status in colorectal cancer from histopathology images using internal cross‑validation

  2026cites this paper
• Effect of Race and Tumor Subsite on Survival Outcome in Early- and Late-Onset Colorectal Cancer

  2026cites this paper
• The Critical Role of Epithelial-Mesenchymal Transition (EMT) in Colorectal Cancer Progression and Therapeutic Outcomes.

  2026cites this paper
• Clinicopathological Features of Right vs. Left Colorectal Carcinomas: Do the Differences Really Matter?

  2026cites this paper
• Nucleolar protein 6 as a potential oncogenic factor in colorectal cancer

  2026cites this paper
• Mutation profiling of KRAS and BRAF in primary tumors and circulating tumor cells of colorectal cancer patients using PNA-LNA molecular switch

  2025cites this paper
• First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

  2025cites this paper
• Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Daily Profile of miRNAs in the Rat Colon and In Silico Analysis of Their Possible Relationship to Colorectal Cancer

  2025cites this paper
• KRAS/NRAS/BRAF mutational profile and association with clinicopathological characteristics in patients with metastatic colorectal cancer

  2025cites this paper
• Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

  2025cites this paper
• Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.

  2025cites this paper
• Oncogenic mutations of clinical significance in colorectal cancer.

  2025cites this paper
• Temporal trends in incidence and mortality of colorectal cancer in Denmark from 2007 to 2022

  2025cites this paper
• Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer

  2025cites this paper
• A compilation of 13 patients with metastatic colorectal cancer and concomitant BRAF and RAS family mutations

  2025cites this paper
• Clinical utility of comprehensive genomic profiling test for colorectal cancer: a single institution prospective observational study

  2025cites this paper
• Prediction of KRAS, NRAS, BRAF, and HER2 Status in Colorectal Cancer Based on Histopathology Images Via Weakly Supervised Deep Learning (Preprint)

  2025cites this paper
• Alteration of miR-21 and miR-24 expression: biomarker for early detection of synchronous metastases in colorectal cancer: a cross-sectional study in Indonesia.

  2025cites this paper
• Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries

  2025cites this paper
• Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer

  2025cites this paper
• Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report

  2025cites this paper
• The Influence of Bisphenol A on the Molecular Biological Characteristics of Human Colon Adenocarcinoma HT-29 Culture Cells

  2025cites this paper
• Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients

  2024influential citation
• First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

  2024cites this paper
• Cancer treatment monitoring using cell-free DNA fragmentomes

  2024cites this paper
• Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review

  2024cites this paper
• CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration

  2024cites this paper
• Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

  2024cites this paper
• Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions

  2024cites this paper
• An Insight into the Peculiarities of Signet-Ring Cell Carcinoma of the Colon – a Narrative Review

  2024cites this paper
• Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.

  2024cites this paper
• Molecular insights from comprehensive genomic profiling data in advanced metastatic colorectal cancer in South Asian population: A retrospective observational study

  2024cites this paper
• Prognostic determinants in cancer survival: a multidimensional evaluation of clinical and genetic factors across 10 cancer types in the participants of Genomics England’s 100,000 Genomes Project

  2024cites this paper
• Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

  2024cites this paper
• A panorama of colon cancer in the era of liquid biopsy

  2024cites this paper
• Personalized Driver Gene Prediction Using Graph Convolutional Networks with Conditional Random Fields

  2024cites this paper
• Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis

  2024cites this paper
• miR-29a expression negatively correlates with Bcl-2 levels in colorectal cancer and is correlated with better prognosis.

  2024cites this paper
• Personalised medicine based on host genetics and microbiota applied to colorectal cancer.

  2024cites this paper
• Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis

  2024cites this paper
• The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis

  2024cites this paper
• New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.

  2024cites this paper
• Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer

  2024cites this paper
• KRAS mutations and their associations with clinicopathological features and survival in Vietnamese non‑polyp colon cancer patients

  2023cites this paper
• Radiogenomics: a key component of precision cancer medicine

  2023cites this paper
• Integrated molecular profiling of RAS, BRAF mutations, and mismatch repair status in advanced colorectal carcinoma: insights from gender and tumor laterality

  2023cites this paper
• New developments in targeted therapy for metastatic colorectal cancer

  2023cites this paper
• Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (2023 edition)

  2023cites this paper
• Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts

  2023cites this paper
• Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

  2023cites this paper
• Journal of Coloproctology

  2023cites this paper
• Pilot radiogenomic evaluation of colorectal cancer - Are there preoperative radiological features of the dMMR phenotype?

  2023cites this paper
• Clinical Analysis of the Colorectal Cohort within the Wales Cancer Biobank: A Study of Outcomes and Genetic Screening

  2023cites this paper
• Analysis Characteristics of Genetic Alterations in Colorectal Cancer

  2023influential citation
• Current advances in detecting genetic and epigenetic biomarkers of colorectal cancer.

  2023cites this paper
• Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC)

  2023cites this paper
• Early-Onset Colorectal Cancer: Current Insights

  2023cites this paper
• Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (V. 2023)

  2023cites this paper
• KẾT QUẢ ĐIỀU TRỊ BƯỚC MỘT CETUXIMAB KẾT HỢP HÓA CHẤT TRONG UNG THƯ ĐẠI TRỰC TRÀNG TÁI PHÁT, DI CĂN

  2023cites this paper
• Update on Emerging Therapies for Advanced Colorectal Cancer.

  2023cites this paper
• Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer

  2023cites this paper
• HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma

  2023cites this paper
• Racial disparities in colorectal cancer clinicopathological and molecular tumor characteristics: a systematic review

  2023cites this paper
• Urachal carcinoma: The journey so far and the road ahead.

  2023cites this paper
• The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1st Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018

  2023cites this paper
• Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?—A systematic review

  2023cites this paper
• Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?

  2023cites this paper
• Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations

  2023cites this paper
• Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

  2023cites this paper
• Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer

  2023cites this paper
• Emerging roles of tyrosine kinases in hepatic inflammatory diseases and therapeutic opportunities.

  2023cites this paper
• Journal of Coloproctology

  2023cites this paper
• Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics

  2022cites this paper
• Molecular Pathogenesis of Colorectal Cancer: Impact of Oncogenic Targets Regulated by Tumor Suppressive miR-139-3p

  2022cites this paper
• Role of RAS signaling in ovarian cancer

  2022cites this paper
• Somatic mutations in colorectal cancer: regional experience

  2022cites this paper
• Genetic alterations shaping tumor response to anti-EGFR therapies.

  2022cites this paper
• Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka

  2022cites this paper
• The Molecular Associations of Signet-Ring Cell Carcinoma in Colorectum: Meta-Analysis and System Review

  2022cites this paper
• A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

  2022cites this paper
• Reduced PTCH2 expression is associated with glioma development through its regulation of the PTEN/AKT signaling pathway.

  2022cites this paper
• Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.

  2022cites this paper
• Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review

  2022cites this paper
• The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study

  2022influential citation
• Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy

  2022cites this paper
• Colorectal liver metastasis: molecular mechanism and interventional therapy

  2022cites this paper
• Mutational profile of KRAS-positive colorectal cancer

  2022cites this paper
• The Systematic Analysis of Exercise Mechanism in Human Diseases

  2022cites this paper
• Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

  2022cites this paper
• The emerging roles of NGS in clinical oncology and personalized medicine.

  2022cites this paper
• A CT-Based Radiomics Nomogram in Predicting the Postoperative Prognosis of Colorectal Cancer: A Two-center Study.

  2022cites this paper
• Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved.

  2022cites this paper
• Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

  2022cites this paper
• Mutation of KRAS in colorectal adenocarcinoma in Greenland

  2022cites this paper
• Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

  2021cites this paper
• Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation

  2021cites this paper
• The Landscape of PIK3CA Mutations in Colorectal Cancer.

  2021cites this paper
• Prognostic Role of Pre-Treatment Carcinoembryonic Antigen and Carbonhydrate Antigen 19-9 in Metastatic Colorectal Cancer

  2021cites this paper
• Perineural Invasion Is a Strong Prognostic Factor but Not a Predictive Factor of Response to Adjuvant Chemotherapy in Node-Negative Colon Cancer

  2021cites this paper